240 related articles for article (PubMed ID: 11393279)
1. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
2. A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice.
Samoto K; Ehtesham M; Perng GC; Hashizume K; Wechsler SL; Nesburn AB; Black KL; Yu JS
Neurosurgery; 2002 Mar; 50(3):599-605; discussion 605-6. PubMed ID: 11841729
[TBL] [Abstract][Full Text] [Related]
3. The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein.
Drolet BS; Perng GC; Cohen J; Slanina SM; Yukht A; Nesburn AB; Wechsler SL
Virology; 1998 Mar; 242(1):221-32. PubMed ID: 9501054
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
7. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
8. Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant.
Drolet BS; Perng GC; Villosis RJ; Slanina SM; Nesburn AB; Wechsler SL
Virology; 1999 Jan; 253(1):96-106. PubMed ID: 9887322
[TBL] [Abstract][Full Text] [Related]
9. A non-consensus branch point plays an important role in determining the stability of the 2-kb LAT intron during acute and latent infections of herpes simplex virus type-1.
Mukerjee R; Kang W; Suri V; Fraser NW
Virology; 2004 Jul; 324(2):340-9. PubMed ID: 15207620
[TBL] [Abstract][Full Text] [Related]
10. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
Kanai R; Tomita H; Shinoda A; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
[TBL] [Abstract][Full Text] [Related]
12. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.
Perng GC; Thompson RL; Sawtell NM; Taylor WE; Slanina SM; Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
J Virol; 1995 May; 69(5):3033-41. PubMed ID: 7707530
[TBL] [Abstract][Full Text] [Related]
13. A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels.
Perng GC; Maguen B; Jin L; Mott KR; Osorio N; Slanina SM; Yukht A; Ghiasi H; Nesburn AB; Inman M; Henderson G; Jones C; Wechsler SL
J Virol; 2002 Feb; 76(3):1224-35. PubMed ID: 11773398
[TBL] [Abstract][Full Text] [Related]
14. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
15. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
16. Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice.
Ghiasi H; Osorio Y; Perng GC; Nesburn AB; Wechsler SL
J Virol; 2001 Oct; 75(19):9029-36. PubMed ID: 11533166
[TBL] [Abstract][Full Text] [Related]
17. Methods for detecting the HSV-1 LAT anti-apoptosis activity in virus infected tissue culture cells.
Jin L; Perng GC; Brick DJ; Naito J; Nesburn AB; Jones C; Wechsler SL
J Virol Methods; 2004 Jun; 118(1):9-13. PubMed ID: 15158063
[TBL] [Abstract][Full Text] [Related]
18. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
19. Regulation of caspase 8- and caspase 9-induced apoptosis by the herpes simplex virus type 1 latency-associated transcript.
Henderson G; Peng W; Jin L; Perng GC; Nesburn AB; Wechsler SL; Jones C
J Neurovirol; 2002 Dec; 8 Suppl 2():103-11. PubMed ID: 12491160
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
